Background The interleukin (IL)-23/IL-17 pathway is central in the pathogenesis of psoriasis. The favourable efficacy and safety of guselkumab, an IL-23-specific monoclonal antibody, has been demonstrated in global phase III studies of plaque psoriasis. Objectives To evaluate the safety, efficacy and pharmacokinetics of single-dose subcutaneous guselkumab in Japanese patients with moderate-to-severe plaque psoriasis. Methods Patients with ≥ 10% of total body surface area involvement and a Psoriasis Area and Severity Index (PASI) ≥ 12 were randomized (5 : 1) to receive guselkumab or placebo in four cohorts of this double-blind, placebo-controlled, single ascending-dose, single-centre study. Safety, pharmacokinetics and clinical response were monitored at baseline and specific time points over a 24-week follow-up period. Results To week 24, 55% (11/20) of patients in the guselkumab group and 50% (2/4) in the placebo group experienced ≥1 adverse event (AE). No deaths, serious AEs or AEs leading to treatment discontinuation were reported. Maximum clinical response was seen at week 16 with PASI 75 (≥ 75% improvement from baseline PASI) response in two of five (10 mg), four of five (30 mg and 300 mg) and three of five (100 mg) patients; and PASI 90 (≥ 90% improvement from baseline PASI) in zero of five (10 mg), three of five (30 mg), two of five (100 mg) and three of five (300 mg) patients. Mean maximum serum concentration (C max ) and area under the curve from time zero to infinity values increased in a dose-proportional manner with a mean terminal half-life of 15Á6-17Á6 days and median time to reach C max of 4-6 days. Conclusions Guselkumab was generally well-tolerated and exhibited sustained high levels of clinical response in Japanese patients with moderate-to-severe psoriasis.
Summary
Background The interleukin (IL)-23/IL-17 pathway is central in the pathogenesis of psoriasis. The favourable efficacy and safety of guselkumab, an IL-23-specific monoclonal antibody, has been demonstrated in global phase III studies of plaque psoriasis. Objectives To evaluate the safety, efficacy and pharmacokinetics of single-dose subcutaneous guselkumab in Japanese patients with moderate-to-severe plaque psoriasis. Methods Patients with ≥ 10% of total body surface area involvement and a Psoriasis Area and Severity Index (PASI) ≥ 12 were randomized (5 : 1) to receive guselkumab or placebo in four cohorts of this double-blind, placebo-controlled, single ascending-dose, single-centre study. Safety, pharmacokinetics and clinical response were monitored at baseline and specific time points over a 24-week follow-up period. Results To week 24, 55% (11/20) of patients in the guselkumab group and 50% (2/4) in the placebo group experienced ≥1 adverse event (AE). No deaths, serious AEs or AEs leading to treatment discontinuation were reported. Maximum clinical response was seen at week 16 with PASI 75 (≥ 75% improvement from baseline PASI) response in two of five (10 mg), four of five (30 mg and 300 mg) and three of five (100 mg) patients; and PASI 90 (≥ 90% improvement from baseline PASI) in zero of five (10 mg), three of five (30 mg), two of five (100 mg) and three of five (300 mg) patients. Mean maximum serum concentration (C max ) and area under the curve from time zero to infinity values increased in a dose-proportional manner with a mean terminal half-life of 15Á6-17Á6 days and median time to reach C max of 4-6 days. Conclusions Guselkumab was generally well-tolerated and exhibited sustained high levels of clinical response in Japanese patients with moderate-to-severe psoriasis.
What's already known about this topic?
• Interleukin (IL)-23/IL-17 is a major pathway underlying the pathogenesis of psoriasis.
• Results support further development of guselkumab in Japanese patients with moderate-to-severe psoriasis.
Psoriasis, an immune-mediated chronic inflammatory skin disorder, affects nearly 2% of the global population. 1 Fortunately, the understanding of the impact of moderate-to-severe psoriasis on physical impairment and quality of life has evolved, as well the acceptance of the need for effective treatments. Guselkumab, a human monoclonal antibody that specifically targets the p19 subunit of IL-23, antagonizes the IL-23/T helper (Th)17 axis and causes a reduction in the inflammatory cascade associated with psoriasis. 6 A comprehensive global development programme, including phase I-III studies, 7, 8, 15 has characterized the favourable efficacy and safety profile of guselkumab in addition to the pharmacokinetic parameters. Although psoriasis is known to more frequently affect Western populations, the prevalence in Asian patients is increasing. 16 A Japanese nationwide epidemiology study reported that 0Á34% of Japanese patients have psoriasis. 16 Considering the high efficacy and favourable safety profile demonstrated in the phase I and II studies available at the time of protocol development, the current study was designed to evaluate the safety, efficacy and pharmacokinetics of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis (registered at ClinicalTrials.gov: NCT01484587). These results, together with global study outcomes, will be used to evaluate continued development in the Japanese population.
Patients and methods

Patients
Adults aged 20-65 years with moderate-to-severe plaque psoriasis defined as ≥ 10% body surface area and a Psoriasis Area and Severity Index (PASI) score of ≥ 12, who have been diagnosed with plaque psoriasis for at least 6 months prior to screening were enrolled. Patients were ineligible if they had a history of chronic or recurrent infectious disease, a history of or concurrent malignancy, or ongoing active infections including tuberculosis. Patients could not participate if they had used any therapeutic agent directly targeted to IL-12, IL-17 or IL-23, within 6 months or five half-lives (t 1/2 ) (whichever was longer), phototherapy within 4 weeks and topical therapy within 2 weeks prior to study agent administration. Concomitant use of systemic immunosuppressants and disease-modifying agents was prohibited during the study. The institutional review board for each study site approved the protocol and the study was conducted in accordance with the ethical principles in the Declaration of Helsinki, consistent with good clinical practices and applicable regulatory requirements. All enrolled patients provided written consent for their participation in the study.
Study design
This phase I, randomized, double-blind, placebo-controlled, single ascending-dose study was conducted at a single centre in Japan between August 2011 and April 2013. Four cohorts of six patients each with psoriasis were randomized (five active : one placebo) to receive a subcutaneous dose of guselkumab (10 mg, 30 mg, 100 mg and 300 mg) or placebo ( Fig. 1) . Dose selection was based on a previously conducted non-Japanese phase I study. 15 Dose escalation to sequential cohorts was guided by safety and tolerability data from previous dose cohorts. Central randomization was implemented in this study based on a computer-generated randomization schedule. The total duration of the study was approximately 30 weeks including a 6-week screening period, a single-dose inpatient administration and a 24-week assessment period.
Study assessments
Safety and efficacy parameters were assessed to week 24. Safety evaluations included physical examination, assessment of adverse events (AEs), measurement of vital signs, laboratory studies (haematology, serum chemistry, lipid panel and urinalysis) and an electrocardiogram (ECG). Efficacy was assessed using the PASI 17 and Physician's Global Assessment (PGA).
Photographs were taken at baseline, day 4, day 7 and at weeks 2, 4 and every 4 weeks thereafter.
Pharmacokinetic assessments
Blood samples were collected at day 1 (1 h before and 8 h after study-agent administration), days 2-5, day 7, and at weeks 2, 4, 8, 12 and 16. Serum samples were analysed using a dissociation-enhanced lanthanide fluorescent immunoassay. Pharmacokinetic (PK) parameters included maximum serum concentration (C max ), time to reach C max (t max ), area under the curve from zero to the time of the last quantifiable concentration (AUC last ), AUC from time zero to infinity (AUC ∞ , calculated as AUC ∞ = AUC last + C last /k z , where C last is the last observed quantifiable concentration, and k z is the terminal elimination rate constant), elimination t 1/2 (calculated as ln2/ k z ), apparent total systemic clearance after extravascular administration (CL/F, calculated as dose/AUC ∞ ) and apparent volume of distribution after extravascular administration [V dz / F, calculated dose/(AUC ∞ 9 k z )].
Immunogenicity assessments and biomarker analysis
Serum samples were collected at baseline and at weeks 2 and 16 for detection of antibodies to guselkumab. A validated electrochemiluminescence immunoassay method was used. Serum samples were collected at baseline and at weeks 4, 8 and 12. IL-17A and IL-17F levels were measured using an ultra-sensitive immunoassay system (Singulex, Alameda, CA, U.S.A.) with the detection limits for IL-17A and IL-17F being 0Á017 pg mL À1 and 0Á39 pg mL À1 , respectively. Data for guselkumab dose groups (30 mg, 100 mg and 300 mg) were combined to increase analytic power. We excluded the data from the 10-mg group in this analysis because of insufficient effect on the PASI score.
Statistical analysis
No formal statistical calculations of sample size were conducted as the study did not involve hypothesis testing. All AEs were reviewed using descriptive statistics. The PK parameters of guselkumab were derived from serum concentration over time using a noncompartmental analysis method as implemented in WinNonlin (Version 6Á2Á1, Certara, Princeton, NJ, U.S.A.) and were summarized with descriptive statistics by treatment group. Systemic exposure parameters (C max , AUC last and AUC ∞ ) vs. dose were represented graphically (data not shown). The proportion of patients achieving a PASI 90 (≥ 90% improvement from baseline PASI); PASI 75 (≥ 75% improvement from baseline PASI); and PASI 50 (≥ 50% improvement from baseline PASI) response at each visit was summarized by treatment group. The proportions of patients achieving PGA scores of cleared or minimal (0 or 1), mild or moderate (2 or 3) or marked or severe (4 or 5) was summarized for each treatment group by visit.
The safety analysis included all randomized patients receiving one or more dose of guselkumab or placebo. All participants receiving one or more dose of guselkumab and who had appropriate serum samples available for evaluation were included in the PK and immunogenicity analysis. Patients who received study treatment and had any efficacy assessments after baseline were included in the efficacy analysis.
Results
Demographic and baseline characteristics
Demographics and baseline characteristics were comparable across all four cohorts (Table 1) . Of the enrolled patients, 22 of 24 completed the study and received the study drug by subcutaneous injection. Two patients discontinued the study; one patient who received placebo withdrew consent and one patient who received 10-mg guselkumab was lost to followup. No patient discontinued the study medication because of AEs (Fig. 1 ).
Safety and tolerability
Guselkumab was generally well-tolerated. To week 24, 55% (11/20) of patients in the guselkumab groups and 50% (2/4) of the placebo group experienced at least one AE ( Table 2) . Two of 20 (10%) patients receiving guselkumab had moderate AEs: one patient who received 10-mg guselkumab had an AE of back pain, and one patient receiving 100-mg guselkumab, experienced an injury of meniscus of the knee joint. No severe AEs were observed. No dose-dependent response in the incidence of AEs was observed in the guselkumab groups.
The most common AEs (≥ 2 patients) reported were pruritus (three patients, followed by folliculitis, nasopharyngitis and injection-site erythema (two patients each) in the guselkumab groups. No deaths, serious AEs or AEs leading to treatment discontinuation were reported.
A total of three out of 20 patients (15%) receiving guselkumab reported AEs (very likely or possibly) related to guselkumab; injection-site erythema, (10-mg group: 1/5, 20%; and 300-mg group: 1/5; 20%) urticaria (100-mg group: 1/5, 20%). No trends or dose-related changes in vital signs, body weight, physical examinations, ECG measurements or haematology and chemistry parameters were observed.
Pharmacokinetics and immunogenicity
Following a single subcutaneous administration, 10-mg, 30-mg, 100-mg or 300-mg guselkumab was slowly absorbed with median t max of approximately 4-6 days across all dose cohorts. After attaining maximum level, guselkumab serum concentrations declined in a monophasic manner. The mean C max and mean AUC ∞ values increased approximately in a dose-proportional manner. The mean CL/F, V dz /F and the mean t 1/2 values (15Á6-17Á6 days) were generally consistent across all guselkumab dose groups (Table 3) .
Of the 20 patients who received guselkumab, one patient in the 10-mg group was positive with a low titre (1 : 10) for guselkumab antibodies at week 2. The neutralizing effect was not assessed in this patient.
Efficacy
PASI 75 responses to guselkumab were observed as early as week 4 and reached a maximum at week 16 when PASI 75 was observed in two of five (10 mg), four of five (30 mg and 300 mg) and three of five (100 mg) guselkumab-treated patients. PASI 90 was seen in zero of five (10 mg), three of five (30 mg), two of five (100 mg) and three of five (300 mg) guselkumab-treated patients at week 16. No patients in the placebo group achieved a PASI 75 or PASI 90 response ( Table 4) .
The maximum clinical response was observed at week 16 (day 112) in all guselkumab dose groups (Fig. 2a) . The median per cent improvement from baseline in PASI score at week 16 (day 112) in the 10-, 30-, 100-and 300-mg dose groups was 63%, 91%, 87% and 91%, respectively, compared with -5% in the placebo group. These PASI responses were generally maintained through week 24. The PASI score over time was consistent with the per cent improvement from baseline in PASI over time. Median PASI scores decreased for all dose groups within 2 weeks of treatment initiation and continued to decrease to day 112 (week 16), after which they were maintained (Fig. 2b) .
The pattern of PGA response was consistent with the PASI response. Sixteen (80%) of 20 guselkumab patients achieved a PGA score of cleared or minimal by week 12 and this percentage was generally maintained to week 24 (Table 5) . No patients in the placebo group achieved this response. Clinical improvement in psoriatic lesions after guselkumab treatment is depicted in Figure 3 . 
Serum biomarker analysis
Significant reductions from baseline were observed in the combined guselkumab groups for the circulating serum IL-17A (P < 0Á001) and IL-17F (P < 0Á001) levels, at weeks 4, 8 and 12 (Fig. 4) . In the placebo group, no meaningful conclusion could be drawn owing to the small sample size.
Discussion
This phase I, single ascending-dose study demonstrated an initial favourable safety and efficacy profile for guselkumab, an IL-23 neutralizing monoclonal antibody, in Japanese patients with moderate-to-severe psoriasis. Single subcutaneous doses of guselkumab were generally safe and well tolerated. The substantial and sustained improvements in psoriasis were consistent across two clinical response measurements (PASI and PGA scores). Across doses studied, guselkumab demonstrated linear pharmacokinetics.
The results of this study support the continued development of guselkumab in Japanese patients with moderate-to-severe psoriasis. Comparable rates of AEs were reported across the combined guselkumab and placebo groups and most AEs were mild in severity. One patient in the 10-mg group was positive for low titre guselkumab antibodies. After a single subcutaneous dose, a substantial number of patients achieved PASI 75 and PASI 90 responses in the 3-mg, 100-mg and 300-mg dose groups that were maintained to week 24. Improvements in PGA were also notable with 80% of guselkumab patients with cleared or minimal disease by week 12.
The safety, efficacy and pharmacokinetic profile of guselkumab observed in this phase I study is consistent with that reported in the global phase I guselkumab psoriasis study. 15 Further, the efficacy and safety up to 1 year in over 2000 patients in a phase II and two phase III studies of guselkumab in a moderate-to-severe psoriasis population have been reported. 8, 18, 19 Administered as a regimen of 100 mg initially at week 0, week 4 and every 8 weeks thereafter, the phase III studies validated the superiority of guselkumab compared with adalimumab, including in difficult-to-treat regional disease. 18, 19 No significant safety concerns were identified.
The results of this study, combined with the global programme, support the central role of IL-23 in the pathogenesis of psoriasis. 11, 12 Ustekinumab is approved for psoriasis in Japan and blocks both IL-12 and IL-23. However, it has been established that IL-23 is a key driver of Th17 cells therefore regulating IL-17A, a central cytokine in the pathogenesis of psoriasis. [20] [21] [22] Additionally, IL-23 stimulates the production of other Th17 cytokines important in skin inflammation (for example IL-22) by other cell types, including innate lymphoid Values expressed as mean (SD), unless otherwise specified. C max , maximum serum concentration; t max , time to reach C max ; AUC last , area under the curve (AUC) from zero to the time of the last quantifiable concentration; AUC ∞ , AUC from time zero to infinity; t 1/2 , half-life; CL/F, total systemic clearance after extravascular administration; V dz /F, volume of distribution after extravascular administration. a n = 3, for two patients only the C max , t max and AUC last were obtained; terminal elimination rate constant (kz) could not be estimated. b n = 4, since the r 2 (adjusted) < 0Á9, t 1/2 , AUC ∞ , CL/F, and V dz /F were excluded from descriptive statistics. Consequently, IL-23 could be seen as the overarching master cytokine in the pathogenesis of psoriasis.
In conclusion, with a more specific mechanism of action, impressive efficacy and a favourable safety profile, guselkumab holds potential as a valuable therapeutic option for the treatment of psoriasis. The results of this study will aid in designing future studies in Japanese patients that assess the long-term safety and efficacy of guselkumab in the Japanese population with moderate-to-severe psoriasis.
